We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Shares of Bristol-Myers Falling After Failed Study, While Its Rival Is Surging
Read MoreHide Full Article
Shares of Bristol-Myers Squibb (BMY - Free Report) fell more than 17% in morning trade Friday after its cancer drug failed to meet targets in a late-stage study.
The company released few details of the study, called Checkmate-026, but it said that it had not met its primary endpoint of improvement in progression-free survival. The drug it was testing, Opdivo, has already been approved to treat some types of cancer, but the company was trying to see if it would be successful in treating advanced non-small cell lung cancer.
Company CEO Giovanni Caforio said in a release that he was “disappointed” with the result with the result but management remains “committed to improving patient outcomes through our comprehensive development program.”
While BMY was falling, shares of its biggest rival Merck (MRK - Free Report) jumped more than 10% at one point, as their drug Keytruda that competes with Opdivo succeeded in a similar trial recently. It should be noted though. Merck played it a bit safer in the patient population it chose, targeting “high expressors” of the PD-L1 ligand, which both Keytruda and Opdivo target through inhibition of the PD-1 protein in cancer cells. Bristol-Meyers went for a broader patient population, potentially winning in a bigger market but increasing its risk for failure.
With the opening decrease of 17%, Bristol Meyers lost about $21 billion in market cap. Year-to-date shares of the company are more than 8% lower. BMY currently has a Zacks Rank #3 (Hold). MRK is currently also a Zacks Rank #3 (Hold), but shares of the company are up more than 16% so far this year.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Shares of Bristol-Myers Falling After Failed Study, While Its Rival Is Surging
Shares of Bristol-Myers Squibb (BMY - Free Report) fell more than 17% in morning trade Friday after its cancer drug failed to meet targets in a late-stage study.
The company released few details of the study, called Checkmate-026, but it said that it had not met its primary endpoint of improvement in progression-free survival. The drug it was testing, Opdivo, has already been approved to treat some types of cancer, but the company was trying to see if it would be successful in treating advanced non-small cell lung cancer.
Company CEO Giovanni Caforio said in a release that he was “disappointed” with the result with the result but management remains “committed to improving patient outcomes through our comprehensive development program.”
While BMY was falling, shares of its biggest rival Merck (MRK - Free Report) jumped more than 10% at one point, as their drug Keytruda that competes with Opdivo succeeded in a similar trial recently. It should be noted though. Merck played it a bit safer in the patient population it chose, targeting “high expressors” of the PD-L1 ligand, which both Keytruda and Opdivo target through inhibition of the PD-1 protein in cancer cells. Bristol-Meyers went for a broader patient population, potentially winning in a bigger market but increasing its risk for failure.
With the opening decrease of 17%, Bristol Meyers lost about $21 billion in market cap. Year-to-date shares of the company are more than 8% lower. BMY currently has a Zacks Rank #3 (Hold). MRK is currently also a Zacks Rank #3 (Hold), but shares of the company are up more than 16% so far this year.
Check Out This Week's Friday Finish Line Podcast, To Get Our Take On This Week's Biggest Financial Stories!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>